Endogenous Repair by the Activation of Cell Survival Signalling Cascades during the Early Stages of Rat Parkinsonism

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Lui, Nga Ping ^a   Chen, Liang Wei ^b   Yung, Wing Ho ^c   Chan, Ying Shing ^d   Yung, Ken Kin Lam ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NESTIN; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN KINASE B;

AKT SIGNALING PATHWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; MAPK SIGNALING PATHWAY; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION;

RATTUS;

EID: 84871225910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051294     Document Type: Article

References (67)

1. Wichmann T, DeLong MR, (1996) Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 6: 751-758.
2. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, et al. (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23: S8-19.
3. Betarbet R, Sherer TB, Greenamyre JT, (2002) Animal models of Parkinson's disease. Bioessays 24: 308-318.
4. Alm PA, (2004) Stuttering and the basal ganglia circuits: a critical review of possible relations. J Commun Disord 37: 325-369.
5. Chen LW, Yung KL, Chan YS, (2005) Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease. Curr Drug Targets 6: 821-833.
6. Lev N, Melamed E, Offen D, (2003) Apoptosis and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 245-250.
7. Alves dC, Dunys J, Brau F, Wilk S, Cappai R, et al. (2006) 6-Hydroxydopamine but not 1-methyl-4-phenylpyridinium abolishes alpha-synuclein anti-apoptotic phenotype by inhibiting its proteasomal degradation and by promoting its aggregation. J Biol Chem 281: 9824-9831.
8. Green PS, Simpkins JW, (2000) Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 18: 347-358.
9. Hamner S, Arumae U, Li-Ying Y, Sun YF, Saarma M, et al. (2001) Functional characterization of two splice variants of rat bad and their interaction with Bcl-w in sympathetic neurons. Mol Cell Neurosci 17: 97-106.
10. Kamada H, Nito C, Endo H, Chan PH, (2007) Bad as a converging signaling molecule between survival PI3-K/Akt and death JNK in neurons after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 27: 521-533.
11. Kim YS, Choi MY, Kim YH, Jeon BT, Lee DH, et al. (2010) Protein kinase Cdelta is associated with 14-3-3 phosphorylation in seizure-induced neuronal death. Epilepsy Res 92: 30-40.
12. Song G, Ouyang G, Bao S, (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9: 59-71.
13. Mebratu Y, Tesfaigzi Y, (2009) How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-1175.
14. Fernando RI, Wimalasena J, (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15: 3266-3284.
15. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, et al. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science 286: 1358-1362.
16. Ungerstedt U, (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5: 107-110.
17. Sachs C, Jonsson G, (1975) Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24: 1-8.
18. Dodel RC, Du Y, Bales KR, Ling Z, Carvey PM, Paul SM, (1999) Caspase-3-like proteases and 6-hydroxydopamine induced neuronal cell death. Brain Res Mol Brain Res 64: 141-148.
19. Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T, (2001) Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp Neurol 169: 163-181.
20. Oiwa Y, Sanchez-Pernaute R, Harvey-White J, Bankiewicz KS, (2003) Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease. J Neurosurg 98: 136-144.
21. Shimohama S, Sawada H, Kitamura Y, Taniguchi T, (2003) Disease model: Parkinson's disease. Trends Mol Med 9: 360-365.
22. Yuan H, Sarre S, Ebinger G, Michotte Y, (2005) Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 144: 35-45.
23. Emborg ME, (2007) Nonhuman primate models of Parkinson's disease. ILAR J 48: 339-355.
24. Schwarting RK, Huston JP, (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50: 275-331.
25. Iancu R, Mohapel P, Brundin P, Paul G, (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 162: 1-10.
26. Katoh-Semba R, Takeuchi IK, Semba R, Kato K, (1997) Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem 69: 34-42.
27. Patapoutian A, Reichardt LF, (2001) Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11: 272-280.
28. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62: 6462-6466.
29. Chen LW, Hu HJ, Liu HL, Yung KK, Chan YS, (2004) Identification of brain-derived neurotrophic factor in nestin-expressing astroglial cells in the neostriatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Neuroscience 126: 941-953.
30. Collier TJ, Dung LZ, Carvey PM, Fletcher-Turner A, Yurek DM, et al. (2005) Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol 191 Suppl 1: S60-S67.
31. Chiocco MJ, Harvey BK, Wang Y, Hoffer BJ, (2007) Neurotrophic factors for the treatment of Parkinson's disease. Parkinsonism Relat Disord 13 Suppl 3: S321-S328.
32. Peterson AL, Nutt JG, (2008) Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5: 270-280.
33. Yacoubian TA, Standaert DG, (2009) Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 1792: 676-687.
34. Ernfors P, Bramham CR, (2003) The coupling of a trkB tyrosine residue to LTP. Trends Neurosci 26: 171-173.
35. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F, (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
36. Saavedra A, Baltazar G, Duarte EP, (2008) Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 86: 186-215.
37. Saha RN, Liu X, Pahan K, (2006) Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1: 212-222.
38. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, et al. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350: 230-232.
39. Dechant G, (2001) Molecular interactions between neurotrophin receptors. Cell Tissue Res 305: 229-238.
40. Grimes CA, Jope RS, (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426.
41. Miller FD, Kaplan DR, (2001) Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 58: 1045-1053.
42. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ, (2002) Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res 62: 6756-6763.
43. Kaytor MD, Orr HT, (2002) The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 12: 275-278.
44. Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y, (2002) An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 277: 34287-34294.
45. Neff F, Noelker C, Eggert K, Schlegel J, (2002) Signaling pathways mediate the neuroprotective effects of GDNF. Ann N Y Acad Sci 973: 70-74.
46. Rao RV, Peel A, Logvinova A, del RG, Hermel E, et al. (2002) Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett 514: 122-128.
47. Mandic A, Hansson J, Linder S, Shoshan MC, (2003) Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 278: 9100-9106.
48. Nakagawa T, Schwartz JP, (2004) Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. Brain Pathol 14: 275-280.
49. Ugarte SD, Lin E, Klann E, Zigmond MJ, Perez RG, (2003) Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK. J Neurosci Res 73: 105-112.
50. Gill SS, Patel NK, Hotton GR, OSullivan K, McCarter R, et al. (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595.
51. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, et al. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57: 298-302.
52. Allan SM, Rothwell NJ, (2001) Cytokines and acute neurodegeneration. Nat Rev Neurosci 2: 734-744.
53. Song H, Stevens CF, Gage FH, (2002) Astroglia induce neurogenesis from adult neural stem cells. Nature 417: 39-44.
54. Wyss-Coray T, Mucke L, (2002) Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35: 419-432.
55. Chen LW, Wei LC, Qiu Y, Liu HL, Rao ZR, et al. (2002) Significant up-regulation of nestin protein in the neostriatum of MPTP-treated mice. Are the striatal astrocytes regionally activated after systemic MPTP administration? Brain Res 925: 9-17.
56. Blum D, Torch S, Nissou MF, Verna JM, (2001) 6-hydroxydopamine-induced nuclear factor-kappa B activation in PC12 cells. Biochem Pharmacol 62: 473-481.
57. Bove J, Prou D, Perier C, Przedborski S, (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2: 484-494.
58. Henning J, Strauss U, Wree A, Gimsa J, Rolfs A, et al. (2008) Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease. Neurosci Res 62: 246-253.
59. Duffy HS, John GR, Lee SC, Brosnan CF, Spray DC, (2000) Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1beta in primary human fetal astrocytes. J Neurosci 20: RC114.
60. Volterra A, Steinhauser C, (2004) Glial modulation of synaptic transmission in the hippocampus. Glia 47: 249-257.
61. Parri HR, Crunelli V, (2001) Pacemaker calcium oscillations in thalamic astrocytes in situ. Neuroreport 12: 3897-3900.
62. Aguado F, Espinosa-Parrilla JF, Carmona MA, Soriano E, (2002) Neuronal activity regulates correlated network properties of spontaneous calcium transients in astrocytes in situ. J Neurosci 22: 9430-9444.
63. Hirase H, Qian L, Bartho P, Buzsaki G, (2004) Calcium dynamics of cortical astrocytic networks in vivo. PLoS Biol 2: E96.
64. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME, (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20: 709-726.
65. Sgambato V, Minassian R, Nairn AC, Hyman SE, (2003) Regulation of ania-6 splice variants by distinct signaling pathways in striatal neurons. J Neurochem 86: 153-164.
66. Oh-hashi K, Kaneyama M, Hirata Y, Kiuchi K, (2006) ER calcium discharge stimulates GDNF gene expression through MAPK-dependent and-independent pathways in rat C6 glioblastoma cells. Neurosci Lett 405: 100-105.
67. Nozaki C, Asai N, Murakami H, Iwashita T, Iwata Y, et al. (1998) Calcium-dependent Ret activation by GDNF and neurturin. Oncogene 16: 293-299.